|
|
|
|
|
|
|
|
|
|
the financing round for CrystalsFirst has just started. The DeepTech biotechnology company from Germany accelerates the development of new drugs with a patented technology platform that combines protein crystallography and artificial intelligence. Located at DESY (Deutsches Elektronen-Synchrotron), one of the world's leading particle accelerator research centers, CrystalsFirst enables 3D structural analysis of proteins and drug molecules with unprecedented speed and resolution.
CrystalsFirst has successfully transitioned from cutting-edge research to the global pharma and biotech market. With international clients in the USA, Japan, South Korea, and Europe – including Merck, KSQ Therapeutics, and Think BioScience – CrystalsFirst already achieved 1.5 million EUR in revenue in 2025.
The company was founded by Dr. Serghei Glinca, co-developer of the technology and former researcher at Philipps University Marburg. Today, it brings together 19 experts from structural biology, protein crystallography, AI, and drug discovery. Existing institutional investors include, among others, BMH Beteiligungs-Management Hessen and IFB Innovationsstarter Hamburg. |
|
|
|
|
|
|
|
|
| INVESTMENT HIGHLIGHTS |
|
|
|
|
| • |
|
DeepTech startup for the acceleration of drug development (Drug Discovery), located at DESY (Deutsches Elektronen-Synchrotron). |
|
|
| • |
|
Game Changer for pharma and biotech companies: 10x faster and unprecedented resolution of 3D structural models. |
|
|
| • |
|
Strong Traction: >1.5 million EUR revenue in 2025, 10 international clients, high customer loyalty thanks to superior results. |
|
|
| • |
|
Institutional Investors: BMH Beteiligungs-Management Hessen and IFB Innovationsstarter Hamburg. |
|
|
| • |
|
Non-Dilutive Research Funding: > 1 million EUR (IFB, PTJ). |
|
|
| • |
|
Trend Proximity Therapeutics: Also addresses diseases previously considered “undruggable”. |
|
|
|
|
|
|
|
|
|
|
|
What does CrystalsFirst do?
CrystalsFirst is a biotechnology company that supports pharma and biotech companies in the development of new drugs. The company combines structural biology with artificial intelligence to analyze the three-dimensional structure of proteins and their interactions with potential active ingredients. This accelerates the identification of new drug candidates and significantly reduces the time and cost involved in drug development.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Companisto GmbH |
|
Köpenicker Str. 154, 10997 Berlin
Managing Director: Tamo Zwinge, LL. M. and David Rhotert
Amtsgericht: Berlin Charlottenburg HRB 132811 B
VAT-ID: DE 276 014 929
Phone: +49 30 330 837 49
Email: service@companisto.com |
|
|
|
|
|
|
|
|
| You receive this newsletter because you have subscribed to it. You can unsubscribe at any time via the unsubscribe link. |
|
| The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity. |
|
|
|
|
|
|
